JP6932342B2 - 肝臓癌を処置するための組成物および方法 - Google Patents

肝臓癌を処置するための組成物および方法 Download PDF

Info

Publication number
JP6932342B2
JP6932342B2 JP2018539985A JP2018539985A JP6932342B2 JP 6932342 B2 JP6932342 B2 JP 6932342B2 JP 2018539985 A JP2018539985 A JP 2018539985A JP 2018539985 A JP2018539985 A JP 2018539985A JP 6932342 B2 JP6932342 B2 JP 6932342B2
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
methyl
heteroaryl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018539985A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019507133A (ja
JP2019507133A5 (enExample
Inventor
リウ，シェン−ユン
チェン，チー−ミン
Original Assignee
ゴールデン バイオテクノロジー コーポレーション
ゴールデン バイオテクノロジー コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゴールデン バイオテクノロジー コーポレーション, ゴールデン バイオテクノロジー コーポレーション filed Critical ゴールデン バイオテクノロジー コーポレーション
Publication of JP2019507133A publication Critical patent/JP2019507133A/ja
Publication of JP2019507133A5 publication Critical patent/JP2019507133A5/ja
Application granted granted Critical
Publication of JP6932342B2 publication Critical patent/JP6932342B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/527—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings
    • C07C49/543—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings to a six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/527—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings
    • C07C49/557—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018539985A 2016-02-17 2017-02-16 肝臓癌を処置するための組成物および方法 Active JP6932342B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662296097P 2016-02-17 2016-02-17
US62/296,097 2016-02-17
PCT/US2017/018236 WO2017143106A1 (en) 2016-02-17 2017-02-16 Compositions and methods for treating liver cancer

Publications (3)

Publication Number Publication Date
JP2019507133A JP2019507133A (ja) 2019-03-14
JP2019507133A5 JP2019507133A5 (enExample) 2020-03-26
JP6932342B2 true JP6932342B2 (ja) 2021-09-08

Family

ID=59625477

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018539985A Active JP6932342B2 (ja) 2016-02-17 2017-02-16 肝臓癌を処置するための組成物および方法

Country Status (9)

Country Link
US (1) US10858307B2 (enExample)
EP (1) EP3416630B1 (enExample)
JP (1) JP6932342B2 (enExample)
KR (1) KR102399856B1 (enExample)
CN (1) CN109069448B (enExample)
AU (1) AU2017219871B2 (enExample)
ES (1) ES2961932T3 (enExample)
TW (1) TWI737683B (enExample)
WO (1) WO2017143106A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025165622A1 (en) * 2024-01-31 2025-08-07 Golden Biotechnology Corporation Therapeutic compositions for treating liver cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI394573B (zh) * 2007-06-14 2013-05-01 國鼎生物科技股份有限公司 Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for Liver Protection
CN101417934B (zh) * 2007-10-24 2012-04-18 国鼎生物科技股份有限公司 分离自牛樟芝萃取物的化合物
FR2987264A1 (fr) * 2012-02-23 2013-08-30 Golden Biotechnology Corp Methodes et compositions pour le traitement des metastases cancereuses
TWI597061B (zh) * 2013-02-20 2017-09-01 國鼎生物科技股份有限公司 治療白血病之方法及組成物
TWI612026B (zh) * 2013-02-20 2018-01-21 國鼎生物科技股份有限公司 環己烯酮組成物及其製造方法

Also Published As

Publication number Publication date
JP2019507133A (ja) 2019-03-14
US20190112258A1 (en) 2019-04-18
EP3416630B1 (en) 2023-10-25
KR20180118634A (ko) 2018-10-31
CA3014057A1 (en) 2017-08-24
CN109069448B (zh) 2021-09-21
US10858307B2 (en) 2020-12-08
AU2017219871A1 (en) 2018-08-16
WO2017143106A1 (en) 2017-08-24
TWI737683B (zh) 2021-09-01
ES2961932T3 (es) 2024-03-14
EP3416630A4 (en) 2019-10-09
AU2017219871B2 (en) 2020-09-03
KR102399856B1 (ko) 2022-05-20
EP3416630A1 (en) 2018-12-26
TW201733976A (zh) 2017-10-01
EP3416630C0 (en) 2023-10-25
CN109069448A (zh) 2018-12-21

Similar Documents

Publication Publication Date Title
TW202014186A (zh) 作為核轉運調節劑之化合物及其用途
JP7689690B2 (ja) ヒドロキシ安息香酸誘導体、その方法および使用
JP2023025088A (ja) Ｈｄａｃ６阻害剤及び造影剤
JP6884800B2 (ja) メマンチン化合物及びその調整並びにその使用
CN109867675A (zh) 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途
JP2021508318A (ja) チューブリン阻害剤
CN104603133B (zh) 用于治疗癌症和免疫抑制的组合疗法
JP6932342B2 (ja) 肝臓癌を処置するための組成物および方法
US20220089531A1 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
CN121219280A (zh) 哌啶二酮类化合物、其制备方法和用途
US12172988B2 (en) Anticancer and antifungal splice modulators
CA3014057C (en) Compositions and methods for treating liver cancer
HK40000360A (en) Compositions and methods for treating liver cancer
CN105906540B (zh) 化合物及其制备方法和应用
EP4067367B1 (en) Oleanane cinnamamide derivative, preparation method therefor, and use thereof
CN115304503B (zh) 一种具有ⅰ型prmt抑制活性的化合物及其应用
RU2829816C1 (ru) Производное циннамида оленана, способ его получения и применение
CN113004268B (zh) 一种抑制肿瘤细胞生长的噻唑化合物及其用途
EP4470608A1 (en) Lysophosphatidylserine analogue, and lysophosphatidylserine analogue-containing phamaceutical composition for treating or preventing fibrosis
RU2768830C9 (ru) Производное биарила, метод его получения и его фармацевтическое применение
RU2768830C2 (ru) Производное биарила, метод его получения и его фармацевтическое применение
WO2018175965A1 (en) Antiestrogens for cancer therapy
CN107325030A (zh) 一类新型反式芪类抗肿瘤剂
WO2021178841A1 (en) Heterocycle containing stat inhibitors and compositions
BR112021018303B1 (pt) Composto inibidor de pequenas moléculas de fatores de transcrição de tead ou sal farmaceuticamente aceitável deste, composição farmacêutica e uso destes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200214

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210419

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210712

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210803

R150 Certificate of patent or registration of utility model

Ref document number: 6932342

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250